ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPIX
CUSIPN/A
Phone778-331-0962
Debt
Debt-to-Equity Ratio0.35
Current Ratio5.29
Quick Ratio5.29
Price-To-Earnings
Trailing P/E Ratio-0.39
Forward P/E Ratio-0.93
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($3.09) per share
Price / Book-1.00
Profitability
EPS (Most Recent Fiscal Year)($8.00)
Net Income$-4,720,000.00
Net MarginsN/A
Return on Equity-13,659.00%
Return on Assets-137.41%
Miscellaneous
Employees15
Outstanding Shares5,780,000
Market Cap$18.27 million
ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions
What is ESSA Pharma's stock symbol?
ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."
When is ESSA Pharma's next earnings date?
What price target have analysts set for EPIX?
2 equities research analysts have issued 1 year price targets for ESSA Pharma's shares. Their predictions range from $0.70 to $0.70. On average, they anticipate ESSA Pharma's stock price to reach $0.70 in the next twelve months. This suggests that the stock has a possible downside of 77.4%. View Analyst Price Targets for ESSA Pharma.
What is the consensus analysts' recommendation for ESSA Pharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ESSA Pharma.
Who are some of ESSA Pharma's key competitors?
Some companies that are related to ESSA Pharma include IMMUTEP LTD/S (IMMP), KemPharm (KMPH), Merrimack Pharmaceuticals (MACK), OASMIA PHARMACE/ADR (OASM), Trillium Therapeutics (TRIL), VIVUS (VVUS), Novan (NOVN), Alimera Sciences (ALIM), SCYNEXIS (SCYX), Imprimis Pharmaceuticals (IMMY), Axsome Therapeutics (AXSM), DiaMedica Therapeutics (DMCAF), Versartis (VSAR), Novelion Therapeutics (NVLN) and BELLUS Health (BLUSF).
Who are ESSA Pharma's key executives?
ESSA Pharma's management team includes the folowing people:
- Dr. David Ross Parkinson, Pres, CEO & Director (Age 68)
- Mr. David S. Wood, Chief Financial Officer (Age 61)
- Mr. Peter A. Virsik, Exec. VP & COO (Age 47)
- Dr. Raymond Andersen, CTO, Sec. & Director (Age 71)
- Dr. Marianne D. Sadar, Chief Scientific Officer & Director (Age 57)
Has ESSA Pharma been receiving favorable news coverage?
Headlines about EPIX stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ESSA Pharma earned a coverage optimism score of 0.01 on Accern's scale. They also gave media coverage about the company an impact score of 46.88 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for ESSA Pharma.
Who are ESSA Pharma's major shareholders?
ESSA Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Omega Fund Management LLC (18.77%) and DRW Securities LLC (0.59%).
Which major investors are buying ESSA Pharma stock?
EPIX stock was purchased by a variety of institutional investors in the last quarter, including Omega Fund Management LLC and DRW Securities LLC.
How do I buy shares of ESSA Pharma?
Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ESSA Pharma's stock price today?
One share of EPIX stock can currently be purchased for approximately $3.10.
How big of a company is ESSA Pharma?
ESSA Pharma has a market capitalization of $18.27 million. The company earns $-4,720,000.00 in net income (profit) each year or ($8.00) on an earnings per share basis. ESSA Pharma employs 15 workers across the globe.
How can I contact ESSA Pharma?
ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962.
MarketBeat Community Rating for ESSA Pharma (NASDAQ EPIX)
MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe EPIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
